Overview
Tesamorelin is an FDA-approved GHRH analog studied extensively for reduction of visceral adipose tissue (VAT). It has become popular in longevity practice for patients with metabolic-syndrome features.
Key benefits
Reduces visceral adipose tissue Improves lipid profile Supports cognitive markers in some studies Recovery support
How it works
Nightly subcutaneous injection; effects on visceral fat typically measurable at 12–26 weeks.
Mechanism
GHRH-receptor agonist increasing endogenous GH and IGF-1, with disproportionate lipolytic effect on VAT.
Who is this for
Adults with elevated visceral fat Metabolic-syndrome patients Longevity patients addressing central adiposity
Considerations & safety
Not indicated in active malignancy. Monitor glucose and IGF-1.
This page is educational and not medical advice. All VitaFlow protocols require evaluation by a licensed Florida physician.
Frequently asked How is this different from Sermorelin?+
Tesamorelin has strong FDA evidence specifically for visceral fat. How long to see fat changes?+
12–26 weeks with lifestyle support. Can I combine with Semaglutide?+
Only under physician supervision. Monitoring?+
IGF-1, fasting glucose, HbA1c.
Related in Peptide Therapy
Ready to feel your best?
Meet with a VitaFlow physician to design a protocol tailored to your goals, biomarkers, and lifestyle.
© 2026 VitaFlow Longevity, LLC. All rights reserved.